IF by "the HCV market" we are talking about HCV drug revenues, THEN there no question that it has decreased. ABBV undercutting on price and further cutting a deal to discount that price cuts the revenue. Any competition on price by GILD, which is to be expected also cuts the revenue.
ij
It is astonishing what foolish things one can temporarily believe if one thinks too long alone ... where it is often impossible to bring one's ideas to a conclusive test either formal or experimental. J.M. Keynes
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.